Skip to main content
. 2021 Feb 10;5(3):e532. doi: 10.1097/HS9.0000000000000532

Figure 2.

Figure 2.

Outcome according to BMI at diagnosis and prior to HSCT (< 25 kg/m2 vs 25-29.9 kg/m2 vs ≥ 30 kg/m2) in AML patients receiving allogeneic HSCT. (A), Nonrelapse mortality and (B) overall survival according to BMI at diagnosis (n = 381). (C), Nonrelapse mortality and (D) overall survival according to BMI prior to HSCT (n = 650). AML = acute myeloid leukemia; BMI = body mass index; HSCT = hematopoietic stem cell transplantation.